{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-002769","form_type":"8-K/A","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.082307+00:00","generated_at":"2026-05-28T02:48:22.596128+00:00","sec_items":["3.01","7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ABVC BioPharma granted additional 180-day Nasdaq bid price compliance extension to July 7, 2025","bullets":["Nasdaq extended deadline from January 6, 2025 to July 7, 2025 for minimum $1.00 bid price requirement.","Company must close at $1.00 or higher for at least 10 consecutive trading days to regain compliance.","ABVC may consider a reverse stock split to meet the bid price requirement.","No immediate impact on Nasdaq listing; stock continues trading under symbol ABVC."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-002769","json":"https://secwatch.observer/filing/0001213900-25-002769.json","markdown":"https://secwatch.observer/filing/0001213900-25-002769.md","text":"https://secwatch.observer/filing/0001213900-25-002769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025002769/0001213900-25-002769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025002769/ea0227316-8ka1_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:48:22.596128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b7c89f81f6d047ea758d5d91bbd0979c64532218","claim":"ABVC BIOPHARMA, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"January 9, 2025, ABVC BioPharma, Inc. (the \"Company\") received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share, as","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025002769/0001213900-25-002769-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001493152-26-019593","ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-04-29T23:59:59+00:00","headline":"INVO Fertility receives Nasdaq deficiency notice for late 10-K filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-019593","json":"https://secwatch.observer/filing/0001493152-26-019593.json","markdown":"https://secwatch.observer/filing/0001493152-26-019593.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226019593/0001493152-26-019593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226019593/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 9, 2025, ABVC BioPharma, Inc. (the \"Company\")\nreceived a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement\nof $1.00 per share, as","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025002769/0001213900-25-002769-index.htm","comparable_excerpt":"April 23, 2026, INVO Fertility, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications\nstaff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company failed to fi","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226019593/0001493152-26-019593-index.htm"}},{"accession":"0001628280-26-039190","ticker":"FTHM","company_name":"Fathom Holdings Inc.","filed_at":"2026-05-29T20:15:13+00:00","headline":"Fathom Holdings receives Nasdaq notice for late Q1 2026 10-Q filing; 60 days to submit plan","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039190","json":"https://secwatch.observer/filing/0001628280-26-039190.json","markdown":"https://secwatch.observer/filing/0001628280-26-039190.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1753162/000162828026039190/0001628280-26-039190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1753162/000162828026039190/fthm-20260522.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 9, 2025, ABVC BioPharma, Inc. (the \"Company\")\nreceived a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement\nof $1.00 per share, as","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025002769/0001213900-25-002769-index.htm","comparable_excerpt":"May 22, 2026, Fathom Holdings Inc. (the “Company”) received a notification letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission (the “Filing Requirement”). In accordance with Nasdaq’s listing rules, the Company has 60 calendar days from the date of the notification letter","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1753162/000162828026039190/0001628280-26-039190-index.htm"}},{"accession":"0001493152-26-025087","ticker":"LASE","company_name":"Laser Photonics Corp","filed_at":"2026-05-22T21:27:31+00:00","headline":"Laser Photonics receives Nasdaq delisting notice for late Q1 2026 10-Q","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025087","json":"https://secwatch.observer/filing/0001493152-26-025087.json","markdown":"https://secwatch.observer/filing/0001493152-26-025087.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807887/000149315226025087/0001493152-26-025087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807887/000149315226025087/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 9, 2025, ABVC BioPharma, Inc. (the \"Company\")\nreceived a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement\nof $1.00 per share, as","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025002769/0001213900-25-002769-index.htm","comparable_excerpt":"received a notice from Nasdaq Listing Qualifications\ndepartment of the Nasdaq Stock Market LLC (“Nasdaq”) stating that since it had not received the Company’s Form 10-Q\nfor the period ended March 31, 2026, the Company does not comply with Nasdaq’s Listing Rules for continued listing. Nasdaq stated\nthat the Company has 60 days to submit a plan to regain compliance with respect to this delinquent report. Nasdaq can grant an exception\nto allow the Company to regain compliance up to a maximum of 180 calendar days from the due date of the Initial Delinquent Filing, or\nNovember 16, 2026. A\ncopy of t","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1807887/000149315226025087/0001493152-26-025087-index.htm"}},{"accession":"0001628280-26-037742","ticker":"RICK","company_name":"RCI HOSPITALITY HOLDINGS, INC.","filed_at":"2026-05-22T20:23:08+00:00","headline":"RCI receives Nasdaq noncompliance notice for late Q2 10-Q; deadline July 20","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-037742","json":"https://secwatch.observer/filing/0001628280-26-037742.json","markdown":"https://secwatch.observer/filing/0001628280-26-037742.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/935419/000162828026037742/0001628280-26-037742-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/935419/000162828026037742/rick-20260520.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 9, 2025, ABVC BioPharma, Inc. (the \"Company\")\nreceived a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement\nof $1.00 per share, as","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025002769/0001213900-25-002769-index.htm","comparable_excerpt":"May 20, 2026, RCI Hospitality Holdings, Inc. (“we,” “us” and the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that we are","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/935419/000162828026037742/0001628280-26-037742-index.htm"}},{"accession":"0001731122-26-000781","ticker":"AVXL","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2026-05-22T12:15:26+00:00","headline":"Anavex receives Nasdaq delinquency notice for late 10-Q filing; deadline July 20, 2026","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000781","json":"https://secwatch.observer/filing/0001731122-26-000781.json","markdown":"https://secwatch.observer/filing/0001731122-26-000781.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000781/0001731122-26-000781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000781/e7667_8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 9, 2025, ABVC BioPharma, Inc. (the \"Company\")\nreceived a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement\nof $1.00 per share, as","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025002769/0001213900-25-002769-index.htm","comparable_excerpt":"May 20, 2026, Anavex Life Sciences Corp. (the “Company”)\nreceived a delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market\nLLC (“Nasdaq”) indicating that, as","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000781/0001731122-26-000781-index.htm"}},{"accession":"0001493152-26-024913","ticker":"GTBP","company_name":"GT Biopharma, Inc.","filed_at":"2026-05-22T12:00:37+00:00","headline":"GT Biopharma receives Nasdaq extension to Nov 16, 2026 to meet $1 minimum bid price","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-024913","json":"https://secwatch.observer/filing/0001493152-26-024913.json","markdown":"https://secwatch.observer/filing/0001493152-26-024913.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/0001493152-26-024913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 9, 2025, ABVC BioPharma, Inc. (the \"Company\")\nreceived a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement\nof $1.00 per share, as","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025002769/0001213900-25-002769-index.htm","comparable_excerpt":"May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the “Company”), received a letter from the Nasdaq Listing Qualifications\nStaff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315226024913/0001493152-26-024913-index.htm"}},{"accession":"0001654954-26-004223","ticker":"ONFO","company_name":"Onfolio Holdings, Inc","filed_at":"2026-05-01T23:59:59+00:00","headline":"Onfolio Holdings regains Nasdaq minimum bid price compliance","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-26-004223","json":"https://secwatch.observer/filing/0001654954-26-004223.json","markdown":"https://secwatch.observer/filing/0001654954-26-004223.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1825452/000165495426004223/0001654954-26-004223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1825452/000165495426004223/onfo_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 9, 2025, ABVC BioPharma, Inc. (the \"Company\")\nreceived a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement\nof $1.00 per share, as","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025002769/0001213900-25-002769-index.htm","comparable_excerpt":"January 6, 2026, Onfolio Holdings Inc. (the “ Company ”) received notice from The NASDAQ Stock Market that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days a","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1825452/000165495426004223/0001654954-26-004223-index.htm"}},{"accession":"0001654954-26-004174","ticker":"AREC","company_name":"American Resources Corp","filed_at":"2026-04-30T23:59:59+00:00","headline":"American Resources receives Nasdaq non-compliance notice for late 10-K filing; has 60 days to submit plan","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-26-004174","json":"https://secwatch.observer/filing/0001654954-26-004174.json","markdown":"https://secwatch.observer/filing/0001654954-26-004174.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590715/000165495426004174/0001654954-26-004174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590715/000165495426004174/arec_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 9, 2025, ABVC BioPharma, Inc. (the \"Company\")\nreceived a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement\nof $1.00 per share, as","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390025002769/0001213900-25-002769-index.htm","comparable_excerpt":"April 24, 2026, American Resources Corporation (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to t","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590715/000165495426004174/0001654954-26-004174-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}